COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab

BACKGROUND: In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup. CASE PRESENTATION: We describe a case of a 32-year-old man with paroxysmal nocturna...

Descripción completa

Detalles Bibliográficos
Autores principales: Shikdar, Sufana, Borogovac, Azra, Mohamad, Elabdallah, Khawandanah, Mohamad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530370/
https://www.ncbi.nlm.nih.gov/pubmed/34674707
http://dx.doi.org/10.1186/s12959-021-00330-6
_version_ 1784586658576859136
author Shikdar, Sufana
Borogovac, Azra
Mohamad, Elabdallah
Khawandanah, Mohamad
author_facet Shikdar, Sufana
Borogovac, Azra
Mohamad, Elabdallah
Khawandanah, Mohamad
author_sort Shikdar, Sufana
collection PubMed
description BACKGROUND: In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup. CASE PRESENTATION: We describe a case of a 32-year-old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection. CONCLUSION: This case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients.
format Online
Article
Text
id pubmed-8530370
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85303702021-10-22 COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab Shikdar, Sufana Borogovac, Azra Mohamad, Elabdallah Khawandanah, Mohamad Thromb J Case Report BACKGROUND: In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in this subgroup. CASE PRESENTATION: We describe a case of a 32-year-old man with paroxysmal nocturnal hemoglobinuria (PNH) undergoing treatment with ravulizumab (Ultomiris) who presented with COVID19 infection. He experienced only mild symptoms and had a rapid recovery from COVID19 infection. CONCLUSION: This case may demonstrate the beneficial effects of ravulizumab on complement mediated inflammatory damage linked with COVID19 infection especially in PNH patients. BioMed Central 2021-10-21 /pmc/articles/PMC8530370/ /pubmed/34674707 http://dx.doi.org/10.1186/s12959-021-00330-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Case Report
Shikdar, Sufana
Borogovac, Azra
Mohamad, Elabdallah
Khawandanah, Mohamad
COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
title COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
title_full COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
title_fullStr COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
title_full_unstemmed COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
title_short COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab
title_sort covid19 infection in a patient undergoing treatment for paroxysmal nocturnal hemoglobinuria (pnh) with ravulizumab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8530370/
https://www.ncbi.nlm.nih.gov/pubmed/34674707
http://dx.doi.org/10.1186/s12959-021-00330-6
work_keys_str_mv AT shikdarsufana covid19infectioninapatientundergoingtreatmentforparoxysmalnocturnalhemoglobinuriapnhwithravulizumab
AT borogovacazra covid19infectioninapatientundergoingtreatmentforparoxysmalnocturnalhemoglobinuriapnhwithravulizumab
AT mohamadelabdallah covid19infectioninapatientundergoingtreatmentforparoxysmalnocturnalhemoglobinuriapnhwithravulizumab
AT khawandanahmohamad covid19infectioninapatientundergoingtreatmentforparoxysmalnocturnalhemoglobinuriapnhwithravulizumab

Ejemplares similares